Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director | June 17, 2026 | June 22, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Chief Scientific Officer | March 29, 2022 | March 31, 2022 |
| Nasus Pharma LtdNSRX · Entity 7254 | Director | March 18, 2026 | March 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16 | Direct | 20,275 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
Karyopharm Therapeutics Inc.
Report date March 29, 2022 · Filed March 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 958,131 |
Reported balance
After 2022-03-29 transaction · row 1
1 source rowRow 1 · 2022-03-29 · Grant · Acquired 60,000 · Balance 958,131 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-03-28 | Direct | 90,000 |
Reported balance
After 2022-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-29 · Grant · Acquired 90,000 · Balance 90,000 F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 713,757 |
Reported balance
Holding disclosure · report date 2022-03-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 713,757 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Nasus Pharma Ltd
Report date March 18, 2026 · Filed March 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2035-12-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2020 Filed Jun 24, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-038717 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,924 Underlying: Common Stock · 7,500 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $20.00 | $150,000.00 |
DisclosureSEC source: 0001209191-20-038717 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $0.03 | $247.50 |
DisclosureSEC source: 0001209191-20-038717 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 357 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 357 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,143 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,424 Underlying: Common Stock · 7,143 shares Expires 2020-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 357 | $16.20 | $5,783.40 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 357 | $0.03 | $11.78 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,143 | $16.38 | $116,995.91 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.12 to $16.58, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,143 | $0.03 | $235.72 |
DisclosureSEC source: 0001209191-20-037226 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 341,061 Underlying: Common Stock · 7,500 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $18.13 | $135,944.25 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 555,122 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.23, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $4.75 | $35,640.00 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 562,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · derivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,303 Underlying: Common Stock · 7,500 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $18.50 | $138,745.50 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.83, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $4.75 | $35,640.00 |
DisclosureSEC source: 0001209191-20-035943 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Stock · 7,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $20.00 | $150,000.00 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $0.03 | $247.50 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,857 Underlying: Common Stock · 7,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $18.65 | $139,840.50 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.23 to $19.07, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $0.03 | $247.50 |
DisclosureSEC source: 0001209191-20-030611 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 348,561 Underlying: Common Stock · 7,500 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · derivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,803 Underlying: Common Stock · 7,500 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $19.63 | $147,209.25 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 555,122 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.49 to $20.00, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $4.75 | $35,640.00 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 562,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $19.63 | $147,204.75 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.49 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,500 | $4.75 | $35,640.00 |
DisclosureSEC source: 0001209191-20-028263 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 356,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $20.64 | $206,404.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 555,122 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.36 to $20.99, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 565,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · derivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $18.61 | $186,115.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.15 to $19.06, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-024147 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 366,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,068 | $22.64 | $46,820.55 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 555,122 F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F6 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.575 to $22.76, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,932 | $22.11 | $175,365.42 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 557,190 F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.57 to $22.55, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 565,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,000 | $22.38 | $67,140.90 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.05 to $23.75, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,000 | $22.58 | $158,053.70 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.095 to $23.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 23:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-018260 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 8,817 | $16.48 | $145,320.91 |
DisclosureSEC source: 0001209191-20-011690 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 555,122 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 8,817 | $16.48 | $145,320.91 |
DisclosureSEC source: 0001209191-20-011690 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,489 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010747 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 65,400 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. F3 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010747 · doc4.xml · derivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,400 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. F2 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-010747 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 563,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-010747 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 376,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $17.43 | $174,294.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 542,139 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.215 to $17.85, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 552,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.